Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFP316)

Drug Name

A-196 Drug Info

Synonyms

1982372-88-2; 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine; A 196; SGC A-196; Cyclopentyl-(6,7-dichloro-4-pyridin-4-yl-phthalazin-1-yl)-amine; GTPL8949; CHEMBL4521971; SCHEMBL17968181; BDBM223981; EX-A4473; s7983; AKOS032945052; ZINC521836458; CCG-268144; CS-5613; NCGC00387310-01; AK685671; BS-15880; HY-100201; A-196, >=98% (HPLC); A-196 (3); Q27074057; 6,7-Dichloro-N-cyclopentyl-4-(4-pyridinyl)-1-phthalazinamine; ClC=1C=C2C(=NN=C(C2=CC=1Cl)NC1CCCC1)C1=CC=NC=C1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Preclinical	[1]

Cross-matching ID

PubChem CID: 117072548
TTD Drug ID: DMFP316

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone-lysine N-methyltransferase KMT5B (KMT5B)	TTJGV7F	KMT5B_HUMAN	Inhibitor	[2]
Histone-lysine N-methyltransferase KMT5C (KMT5C)	TT7H3YM	KMT5C_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
2	The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324.